Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
The Supreme Court refused to overturn a precedent that strengthened the power of government regulators in a closely watched case that could have had broad ramifications for...Politicsread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
The red-hot gold trade is cooling off on Wednesday, and Mark Newton of Newton Advisors says the charts point to further weakness to come.Trading Nationread more
A new report from the financial research firm Leerink, which has been closely covering Amazon's moves in health care, says Amazon is expanding the team that's exploring a move into the pharmacy business.
Researchers at Leerink interviewed an anonymous former senior Amazon employee, who described an exploratory team at Amazon that was once 7 to 8 people, and is now 30 to 40.
The goal appears to be to ensure its customers stay loyal and that all their needs, including health and medical, are serviced on Amazon.com.
Amazon's entry into the pharmaceutical business seems inevitable to many in the health sector, particularly in light of the $3 billion market opportunity, and Leerink thinks it's a matter of "when," not "if."
"Ultimately, Amazon is looking to bolster its Prime membership program, which by signing up for a subscription provides customers with benefits including free shipping, expedited delivery, and other perks," the report states.
"Amazon saw the inclusion of pharmaceutical drugs as a natural add-on to its existing product offerings."
Amazon CEO Jeff Bezos has eyed the pharmacy business for years, dating back to an investment in the startup Drugstore.com in the 1990s. That business was eventually acquired by Walgreens, and later shuttered.
"The specialist indicated that Amazon's decision to enter pharmacy has been in the works for some time," the report reads.
As CNBC has reported, Amazon has been busy in the last year meeting with folks across the industry, including generic drug makers, to figure out how it can break into the space.
The consumables team, led by Eric French, initially kicked off the research process. That team also includes the company's groceries product. In May, the company started interviewing for a pharmacy general manager to lead the team, and it has been looking to recruit health experts for months -- most recently, a health privacy lead. Amazon held exploratory talks in November with generic-drug makers like Sandoz and Mylan.
Amazon's latest high-profile health care hire is Martin Levine, a doctor who specializes in new models of patient care.
Some have speculated that Amazon could be a key player in bringing down drug prices.
But Leerink's analysts said the former member of Bezos' senior executive team suggested that Amazon will aim to match the lowest prices on the market, rather than beating them.
The note also says that Amazon will probably sell drugs directly to consumers, and build a platform open to all suppliers, similar to its Marketplace model. That could further spur price competition among drug makers.
Overall, Amazon's move into the pharmacy business may seem like a foregone conclusion, but don't expect it to happen tomorrow. Some drug supply chain experts say that Amazon has lower-hanging fruit to explore first in the health care space, like selling cash-pay generic drugs and medical supplies.
"Its first and best opportunity remains in the cash-pay market for generic prescriptions," said Adam Fein, president of Pembroke Consulting.